SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Inc. ("ZYUS"), a Canadian life sciences company leading scientific research and development in phyto-therapeutics, announced today that it has partnered with recognized telehealth provider, HelloMD, to help prospective patients access independent medical advice. This is an important step to providing Canadians access to ZYUS’ first generation cannabinoid-based formulations. Patients can schedule a free online consultation with a HelloMD licensed healthcare practitioner (HCP) by visiting www.zyus.ca.
A Commitment to Good Health
HelloMD is a leading virtual healthcare platform for medical services in Canada, offering patients confidential medical advice from registered HCPs through a video-enabled computer or smartphone. The free service is available in English and French, with consultations lasting up to 30 minutes. Patients can speak to HelloMD’s HCPs about their medical history, be educated, and authorized to purchase medical cannabinoid formulations, if the HelloMD’s HPC determines it is the right approach for the individual.
“We are proud to launch this strategic relationship with HelloMD to continue to offer the highest standard of compassionate care to patients and to increase access to healthcare practitioners that are educated about cannabinoid-based formulations and the transformational impact they can have on patient outcomes,” said Brent Zettl, ZYUS CEO. “In our current climate, Canadians need to be cautious about leaving their homes, but that doesn’t mean they have to compromise on living life with difficult symptoms, such as chronic pain. We are excited to increase patient access through telehealth and to welcome prospective patients to ZYUS.”
“HelloMD’s unique platform has helped over thousands of patients gain access to qualified and educated medical advice, from the comfort of their own homes, to determine whether cannabinoids may an option for them,” said Larry Lisser, Chief Executive Officer of HelloMD. “With ZYUS’ team’s strong reputation in the industry and their recent launch direct to patient sales in Canada, this alliance offers the ideal opportunity to introduce more qualified patients to the benefits of medical cannabis.”
Connecting with a Healthcare Practitioner
Patients looking to schedule a free online consultation with a HelloMD licensed healthcare practitioner can follow this simple process:
- Visit www.ZYUS.ca and click on the “Schedule a Free Consultation” button on the homepage, which will then take patients to the HelloMD portal.
- Enter patient information to build an online profile.
- Book an appointment with one of HelloMD’s licensed healthcare practitioners.
Supporting Patients from Coast-to-Coast
ZYUS’ alliance with HelloMD is just one of the many steps the company has taken over the past two years to help improve patient outcomes. The company is also proud to announce the launch of a dedicated French-language version of its website, ZYUS.ca/fr/. Starting today, registered patients can place orders directly from ZYUS.ca/fr/ in French. This newly-launched French website is an important step in helping registered medical patients across Canada access ZYUS’ first generation cannabinoid formulations in their preferred language.
Prospective patients or HCPs seeking more information on ZYUS or its products can visit ZYUS.ca or speak to a member of the ZYUS Patient Care Centre in English or French at 1-833-713-CARE (2273).
About HelloMD
HelloMD is a leading digital platform for alternative healthcare, and has facilitated more than 100,000 virtual consults between patients and licensed practitioners. With its mature tech platform, exceptional patient support and flexible business models, the company's B2B solutions help pharmacies, clinics and producers onboard to deliver world-class, virtual care to existing and new medical cannabis patients. Visit HelloMD
About ZYUS Life Sciences Inc.
ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of innovative cannabinoid-based therapeutics and product candidates. Through clinical research and IP development, we intend to deliver high-quality oils, gel-caps, topical creams and other cannabinoid-based therapeutics and product candidates to patients worldwide. The ZYUS vision is to elevate cannabinoids as a standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients’ lives. ZYUS: Advancing the Science of Well-Being. Visit www.zyus.com.
Forward-Looking Information
This news release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of ZYUS to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These forward-looking statements include, but are not limited to, expectations with respect to our business plans, research activities, product lines and patient services.
Often, but not always, forward-looking statements can be identified by the use of words such as “expects,” “expected,” “expectation,” “anticipates,” “believes,” “intends,” “estimates,” “predicts,” “continues,” “potential,” “targeted,” “plans,” “possible” and similar expressions, or statements that events, conditions or results “will,” “may,” “could,” “would” or “should” occur or be achieved, or the negative of these terms or other comparable terminology. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.
Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.
Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. ZYUS does not assume any obligation to update or revise any forward-looking statements or information respecting proposed patient services or product offerings, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
